The Russian sovereign fund, which supported the country’s vaccine opposing coronavirus disease (Covid-19), rejected the complaint about the protection of Sputnik V after Western experts warned that they opposed its use until testing was passed around the world and regulatory action was taken.
“With this (post), we are answering all the questions from the West that have been diligently asked over the past 3 weeks, frankly with the transparent aim of tarnishing the Russian vaccine,” said Kirill Dmitriev, director of Russia’s Direct Investment Fund. . (RDIF).
Read also: India records the one-day peak with 86,432 new instances of Covid-19; death toll reaches 69561
“All boxes are checked. Right now . . . we’ll start asking questions about some of the Western vaccines,” he told Reuters.
Dmitriev complained that some politicians and the media were focusing on studies that led to the progression of the vaccine, but were busy with the negative exposure opposed to Russia.
The vaccine, called Sputnik-V in homage to the world’s first satellite introduced through the Soviet Union, is a human adenoviral vector vaccine fighting Covid-19.
Dmitriev also praised India for expressing interest in the production of the vaccine.
“India has been a very important spouse of Russia. India is one of the leading generating countries. About 60% of all international vaccines are produced in India. We have a close conversation with the relevant ministries and the Indian government and the country’s main manufacturer. “regarding the production location of the Sputnik V vaccine in India,” he said, according to the ANI.
Read also: Covid-19 Vaccine Developers’ Plan Commitment, Russian Shot ‘Passes Early Test’: Everything You Need to Know
The effects of Sputnik V clinical trials were published on Friday and clinical trials showed that 76 participants participating in the trial developed immune responses. The study team said the VECTOR-based COVID-19 rAd26 and rAd5 vaccine “induces cellular immune responses and fun participants,” based on the effects published Friday through the medical journal The Lancet.
Study participants were followed for 42 days, and scientists reported that the pattern of test participants was small and that no placebo or vaccines were used. The Lancet review indicated that two Russian hospitals were enrolled that involved healthy men and women between the ages of 18 and 36. between June 18 and August 3.
The one led through Dr. Denis Logunov of the NF Gamaleya National Research Center for Epidemiology and Microbiology in Moscow said that the participants had won a “heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 vector ( rAd26) and an adenovirus. type five vector (rAdfive), either carrying the complex gene for the severe acute respiratory syndrome coronavirus 2 glycoprotein (SARS-CoV-2) (rAd26-S and rAdfive-S). »
The written examination through Logunov and his team of researchers noted that there were no side effects for some “common systemic and local reactions”.
The study stated: “The maximum non-unusual systemic and local reactions were injection site pain (44 [58%]), hyperthermia (38 [50%), headache (32 [42%]), asthenia (21 [28]) )]) and joint and muscle aches (18 [24%]). Most systemic and local reactions were benign. Changes in biological variables were mild and transient. In volunteers who won both parts of the vaccine (rAd26-S and rAd5-S), the maximum adverse occasions occurred after the time of vaccination (annex pp. 5-7). No adverse occasion, either Phase 1 or Phase 2, led to the removal of a player from the examination or withdrawal of the drug examined. »
Criticism of Russia’s Sputnik V continues as experts say approval has not been mature. Russian President Vladimir Putin’s daughter also among the participants and at a cabinet assembly said her daughter felt good.
“I know that [the vaccine] works effectively, is helping to expand higher immunity, and has undergone all mandatory testing,” Putin said.
According to Lancet’s report, Peter Openshaw, professor of experimental medicine at Imperial College London, raised considerations about the effectiveness of the vaccine based on the immune reaction. “The immune reaction may not be directly proportional to the degree of coverage; can only be found in large-scale trials,” he said.
“item. title”